How Pharma Companies Evaluate Opportunities
The engine behind every defensible go/no-go.
Inside the decision intelligence engine pharma companies use to evaluate every asset, indication and BD opportunity — the steps, inputs and decision rules.
"What does our opportunity-evaluation engine need to look like to make defensible go/no-go calls every time?"
Best-in-class pharma evaluation engines run a standardized pipeline of clinical, commercial, BD and capability scoring — with documented assumptions and audited outcomes.
The opportunity evaluation engine is the core of decision intelligence in pharma. Teams that operate it defensibly outperform those that re-debate the same questions opportunity-by-opportunity.
What we’re seeing in the data.
Standardization beats brilliance
Consistent rubrics outperform episodic genius.
Documented assumptions are leverage
Every score traceable to a source.
Audit outcomes vs scores
Calibrate scoring against realized outcomes.
Cross-functional in real time
BD + R&D + commercial + finance score same opportunity together.
How to think about it.
-
01
Standardize input pipeline
Same data sources, same definitions.
-
02
Score on rubric
NPV / PoS / fit / capability / competition / time.
-
03
Document assumptions
Source-linked, auditable.
-
04
Cross-functional review
Calibrated scoring committee.
-
05
Audit outcomes
Track realized vs scored.
What separates a good answer from a defensible one.
Independent scoring, then debate.
Stale inputs corrupt outputs.
Pre-defined go/no-go thresholds.
Annual outcome calibration.
Where the signal comes from.
Common questions.
How long to build a real evaluation engine?
A working version in 12–16 weeks; calibrated, audited version takes 12 months.
Can it replace IC committee judgment?
No — it sharpens IC judgment by giving them defensible inputs.
Want this answered on your data?
We build decision systems on top of analyses like this — so the next question takes minutes, not weeks.
Talk to a strategist